An easy-to-operate platform that supports whole blood direct testing with results available in as fast as 3 minutes. It offers high detection throughput of up to 450 tests per hour, includes a built-in thermal printer, and features dedicated tuberculosis detection functionality to provide efficient ...
Manufactured by
China
Xenta Biomedical Science Co., Ltd, founded in December 2021 and headquartered in Guangzhou Development District, is a national high-tech enterprise focused on the R&D, registration, and commercialization of in vitro diagnostic (IVD) reagents and devices. With fully paid-up capital of RMB 10 million, the company is led by a team of returnee PhDs with strong international research and industry experience. It is dedicated to developing innovative POCT technology platforms under the philosophy of "Faster, Better, and More Accessible". The company drives innovation through R&D centers in Guangzhou, Xiamen, and overseas. Using its proprietary dry light-excited chemiluminescence POCT platform, it has developed leading product series and managed major national research projects. The company has published over 20 SCI papers, holds 70 patents, has obtained more than 60 EU CE certifications, and 12 FDA approvals in the United States. Currently, several product lines are actively striving for NMPA certification. Its pipeline covers key areas including cardiovascular, inflammation, oncology, hormone, and infectious diseases, demonstrating end-to-end capabilities from R&D to global commercialization. The core team comprises graduates from top universities such as Texas A&M University, Xiamen University, Sanford-Burnham Medical Research Institute, and Sun Yat-sen University, possessing multidisciplinary expertise in biomedicine, engineering, and law. The co-founders have extensive experience from leading IVD companies, having previously guided teams to achieve annual revenues exceeding several hundred million yuan and secure over 200 product certifications worldwide. Since its establishment, Xenta Biomedical Science Co., Ltd has raised tens of millions in funding and obtained ISO 13485 certification, supporting its global expansion.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
ReLIA Bioengineering(Jiangsu), Inc
China · 2 relevant products
Beijing Zhongjian Antai Diagnostic Co., Ltd.
China · 1 relevant product
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
Hangzhou Fanttest Biotech Co., Ltd.
China · 1 relevant product
Shenzhen Microprofit Biotech Co., Ltd
China · 3 relevant products
B&C Biological
China · 1 relevant product
Biomerica, Inc.
United States · 1 relevant product
SA Scientific Ltd.
United States · 1 relevant product
Vitrosens Biyoteknoloji Anonim Sirketi
Türkiye · 1 relevant product
Shenzhen Kingfocus Biomedical Engineering Co., Ltd.
China · 1 relevant product
24 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 41 closest product alternatives
ReLIA Bioengineering(Jiangsu), Inc · China
A diagnostic platform for point-of-care testing (POCT) that uses immunofluorescence technology for rapid and accurate detection. The platform features precise temperature control, multiple connectivity options, and automatic sample identification to enable quick diagnostic testing.
Beijing Zhongjian Antai Diagnostic Co., Ltd. · China
Fluorescence quantitative immunoassay platform for in vitro diagnostic testing of infectious diseases, respiratory pathogens, and gastrointestinal markers. The system enables quantitative analysis using fluorescence immunoassay technology with Class II medical device certification across multiple regulatory markets. Supports high-throughput diagnostic workflows in clinical laboratories and reference testing facilities.
ReLIA Bioengineering(Jiangsu), Inc · China
A diagnostic platform utilizing two-way lateral flow technology for point-of-care testing. It provides rapid detection capabilities with precise temperature control, diverse connectivity options, and automatic sample recognition for efficient clinical diagnostics.
Guangzhou Wondfo Biotech Co., Ltd. · China
Immunofluorescence-based diagnostic platform for detection and identification of specific antigens or antibodies in clinical samples. Provides fluorescence-based results for rapid point-of-care and laboratory testing.
Hangzhou Fanttest Biotech Co., Ltd. · China
Comprehensive rapid testing platform for multiple disease detection including respiratory and tropical infectious diseases. The platform supports versatile in vitro diagnostic applications across healthcare settings.
Shenzhen Microprofit Biotech Co., Ltd · China
CE-marked fluorescence immunoassay (FIA) analyzer for quantitative point-of-care testing. The MF-T1000 platform delivers rapid diagnostic results with 92.9%+ sensitivity, supporting respiratory combo tests (4-in-1/9-in-1 configurations) for clinical laboratories and healthcare facilities.
B&C Biological · China
A fluorescence-based immunoassay platform from the POCT series designed for rapid diagnostic testing. The SF-100 platform enables high-sensitivity and high-precision immunofluorescence detection for various clinical analytes and sample types.
Biomerica, Inc. · United States
A point-of-care diagnostic platform supporting manual to high-throughput ELISA testing with easy automation capabilities. Enables laboratory-accurate results at the point-of-care.
SA Scientific Ltd. · United States
High-sensitivity diagnostic test platform utilizing fluorescent-based lateral flow technology. Enables rapid automated detection with enhanced sensitivity compared to visual membrane-based tests.
Vitrosens Biyoteknoloji Anonim Sirketi · Türkiye
Immunofluorescence-based diagnostic platform for infectious disease detection providing accurate and fast results.
Shenzhen Kingfocus Biomedical Engineering Co., Ltd. · China
Quantum dot fluorescence-based platform for in vitro diagnostic applications. Supports development of various immunological assays with enhanced optical properties and batch consistency.
Shenzhen YHLO Biotech Co., Ltd. · China
An indirect immunofluorescence technology platform for serological testing and antibody detection. The system is utilized for diagnosis of autoimmune and infectious diseases through fluorescence-based immunoassay methodology.
29 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products